Xalud Therapeutics, founded in San Francisco, is a clinical-stage biotechnology company focused on developing non-viral gene therapies to treat chronic inflammation. Their core mission is to restore immune system homeostasis through innovative plasmid DNA (pDNA)-delivered gene therapy. Xalud's primary market focus is on addressing pathologic inflammation, which is a key factor in numerous chronic diseases. Their pioneering approach aims to create a new paradigm in gene therapy delivery, offering potential treatments for conditions that currently have limited options.

Notable figures affiliated with Xalud Therapeutics include leading scientists and industry experts in gene therapy and immunology. The company has garnered significant interest from prominent biotech investors, reflecting confidence in their innovative platform. Key achievements include advancing their gene therapy candidates into clinical trials, demonstrating promising preclinical results, and establishing strategic partnerships to further their research and development. Xalud Therapeutics is poised to make a substantial impact on the treatment of chronic inflammatory diseases, potentially transforming patient care and outcomes.